» Articles » PMID: 31120497

Age at Seroconversion, HLA Genotype, and Specificity of Autoantibodies in Progression of Islet Autoimmunity in Childhood

Overview
Specialty Endocrinology
Date 2019 May 24
PMID 31120497
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Children with initial autoantibodies to either insulin (IAA) or glutamic acid decarboxylase (GADA) differ in peak age of seroconversion and have different type 1 diabetes (T1D) risk gene associations, suggesting heterogeneity in the disease process.

Objective: To compare the associations of age at seroconversion, HLA risk, and specificity of secondary autoantibodies with the progression of islet autoimmunity between children with either IAA or GADA as their first autoantibody.

Design And Methods: A cohort of 15,253 children with HLA-associated increased risk of T1D participated in a follow-up program in which islet autoantibodies were regularly measured. The median follow-up time was 6.7 years. Spearman correlation, Kaplan-Meier survival plots, and Cox proportional-hazard models were used for statistical analyses.

Results: Persistent positivity for at least one of the tested autoantibodies was detected in 998 children; 388 of children progressed to clinical T1D. Young age at initial seroconversion was associated with a high probability of expansion of IAA-initiated autoimmunity and progression to clinical diabetes, whereas expansion of GADA-initiated autoimmunity and progression to diabetes were not dependent on initial seroconversion age. The strength of HLA risk affected the progression of both IAA- and GADA-initiated autoimmunity. The simultaneous appearance of two other autoantibodies increased the rate of progression to diabetes compared with that of a single secondary autoantibody among subjects with GADA-initiated autoimmunity but not among those with IAA as the first autoantibody.

Conclusions: Findings emphasize the differences in the course of islet autoimmunity initiated by either IAA or GADA supporting heterogeneity in the pathogenic process.

Citing Articles

Risk for progression to type 1 diabetes in first-degree relatives under 50 years of age.

Urrutia I, Martinez R, Calvo B, Marcelo I, Saso-Jimenez L, Martinez de Lapiscina I Front Endocrinol (Lausanne). 2024; 15:1411686.

PMID: 39188918 PMC: 11345149. DOI: 10.3389/fendo.2024.1411686.


Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles.

Ghalwash M, Anand V, Ng K, Dunne J, Lou O, Lundgren M Diabetes Care. 2024; 47(8):1424-1431.

PMID: 38861550 PMC: 11272969. DOI: 10.2337/dc24-0198.


Network Cluster Analysis of PPI and Phenotype Ontology for Type 1 Diabetes Mellitus.

Zaeifi D, Azarnia M Iran J Biotechnol. 2024; 22(1):e3502.

PMID: 38827336 PMC: 11139444. DOI: 10.30498/ijb.2024.361840.3502.


Distinct cellular immune responses in children en route to type 1 diabetes with different first-appearing autoantibodies.

Starskaia I, Valta M, Pietila S, Suomi T, Pahkuri S, Kalim U Nat Commun. 2024; 15(1):3810.

PMID: 38714671 PMC: 11076468. DOI: 10.1038/s41467-024-47918-w.


Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes.

Hirvonen M, Lietzen N, Moulder R, Bhosale S, Koskenniemi J, Vaha-Makila M Sci Rep. 2023; 13(1):15941.

PMID: 37743383 PMC: 10518308. DOI: 10.1038/s41598-023-43039-4.